Articles related to HEALTH OUTCOMES

In this comprehensive analysis of 2,853 TTS patients, beta-blocker therapy demonstrated a significant 29% reduction in mortality risk during follow-up, particularly within the first year after discharge.

Fixed-duration venetoclax-based therapy demonstrates sustained efficacy in CLL, with 65.2% of first-line patients remaining treatment-free five years after completion.

Research demonstrates that excessive consumption of negative news correlates with a nine-fold increase in acute stress symptoms, suggesting a need for clinical awareness of patients’ media consumption patterns.

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.

The bRIGHT study demonstrates that T-TEER using the TriClip system can lead to sustained TR reduction and quality of life improvements in a diverse, real-world population with advanced tricuspid valve disease.

Clinicians treating cancer and kidney disease patients prescribed antidepressants at rates similar to outpatient psychiatrists, highlighting the prevalence of depression management across specialties.